Sugi Predict

Sugi Predict / Compounds / SCHEMBL1475701

SCHEMBL1475701

SCHEMBL1475701

CC(C)(c1c(F)cc(C2CC2C(=O)O)cc1F)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 5/20 0.38
▸ FFAR4 Q5NUL3 4/20 0.35
▸ EPHX2 P34913 1/20 0.34
▸ CYP4F2 P78329 2/20 0.33
▸ CYP4A11 Q02928 2/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ IDO1 P14902 2/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ GRM2 Q14416 1/20 0.33
▸ RARA P10276 1/20 0.32
▸ RARB P10826 1/20 0.32
▸ RARG P13631 1/20 0.32
▸ RXRA P19793 1/20 0.32
▸ RXRB P28702 1/20 0.32
▸ RXRG P48443 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1473393 0.86 FFAR1 (0.41) FFAR1FFAR4EPHX2CYP4F2CYP4A11
SCHEMBL1474209 0.81 CA1 (0.34) —
SCHEMBL1474216 0.76 FFAR1 (0.50) FFAR1EPHX2HDAC4IDO1HRH3
SCHEMBL1473296 0.73 FFAR1 (0.44) FFAR1FFAR4EPHX2CYP4F2CYP4A11
SCHEMBL10288354 0.72 FFAR1 (0.46) FFAR1FFAR4CYP4F2CYP4A11HDAC4
SCHEMBL7002048 0.72 FFAR1 (0.46) FFAR1FFAR4CYP4F2CYP4A11HDAC4
SCHEMBL10253910 0.72 FFAR1 (0.46) FFAR1FFAR4CYP4F2CYP4A11HDAC4
SCHEMBL15196464 0.71 FFAR1 (0.50) FFAR1FFAR4CYP4F2CYP4A11
SCHEMBL12915852 0.71 FFAR1 (0.50) FFAR1FFAR4CYP4F2CYP4A11
SCHEMBL7655989 0.71 FFAR1 (0.50) FFAR1FFAR4CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861359-B1 N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER (US) 2012-11-14 — — EP disclosed
US-20110152326-A1 SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS HANAZAWA TAKESHI 2011-06-23 — — US disclosed
US-7915448-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2011-03-29 — — US disclosed
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS PFIZER INC 2010-02-11 — — US disclosed
US-7622589-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2009-11-24 — — US disclosed
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER, INC. 2006-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists CNR1, HVCN1, CNR2 FFAR1 21/4885FFAR4 298/4885EPHX2 3100/4885
US-20110152326-A1 SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS OPRL1, CNR1, TRPV1 FFAR1 91/4885FFAR4 215/4885EPHX2 1371/4885
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS CNR1, HVCN1, CNR2 FFAR1 21/4885FFAR4 307/4885EPHX2 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.